BioMarin Pharmaceutical (BMRN) Reports Mixed Q2 Earnings; Guides FY08
More News related to BMRN
- Benchmark Capital Upgrades BioMarin (BMRN) to Buy
- Morning Movers: Satyam (SAY) Sinks After Chairman Discloses Fraud, Family Dollar (FDO) Up On Results
- BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
- After-Hours Movers 1/6: La Jolla (LJPC), NetScout (NTCT), Interwoven (IWOV) Higher; SMSC (SMSC), IXYS (IXYS), F5 (FFIV), Global Payments (GPN), Alcoa (AA) Lower
- BioMarin (BMRN) and La Jolla Pharmaceutical (LJPC) In Agreement To Develop Riquent
More News related to Earnings
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) reports Q2 EPS of $0.10, versus the analyst estimate of $0.03. Revenues for the quarter were $64.2 million, versus the consensus of $66.3 million.
Sees FY08 revs of $288-$326 million, versus the consensus of $312.5 million.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.33Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
